MCID: PTT037
MIFTS: 44

Pituitary Tumors

Categories: Rare diseases

Aliases & Classifications for Pituitary Tumors

MalaCards integrated aliases for Pituitary Tumors:

Name: Pituitary Tumors 53 54 42
Pituitary Neoplasms 71
Pituitary Tumor 58

Classifications:



External Ids:

UMLS via Orphanet 72 C0032019
Orphanet 58 ORPHA304055
UMLS 71 C0032019

Summaries for Pituitary Tumors

NINDS : 53 The pituitary is a small, bean-sized gland that is below the hypothalamus, a structure at the base of the brain, by a thread-like stalk that contains both blood vessels and nerves.  It controls a system of hormones in the body that regulate growth, metabolism, the stress response, and functions of the sex organs via the thyroid gland, adrenal gland, ovaries, and testes.  A pituitary tumor is an abnormal growth of cells within the pituitary gland.  Most pituitary tumors are benign, which means they are non-cancerous, grow slowly and do not spread to other parts of the body; however they can make the pituitary gland produce either too many or too few hormones, which can cause problems in the body. Tumors that make hormones are called functioning tumors, and they can cause a wide array of symptoms depending upon the hormone affected.  Tumors that don’t make hormones are called non-functioning tumors.  Their symptoms are directly related to their growth in size and include headaches, vision problems, nausea, and vomiting.  Diseases related to hormone abnormalities include Cushing’s disease, in which fat builds up in the face, back and chest, and the arms and legs become very thin; and acromegaly, a condition in which the hands, feet, and face are larger than normal.  Pituitary hormones that impact the sex hormones, such as estrogen and testosterone, can make a woman produce breast milk even though she is not pregnant or nursing, or cause a man to lose his sex drive or lower his sperm count.  Pituitary tumors often go undiagnosed because their symptoms resemble those of so many other more common diseases.

MalaCards based summary : Pituitary Tumors, also known as pituitary neoplasms, is related to prolactin producing pituitary tumor and tsh producing pituitary tumor. An important gene associated with Pituitary Tumors is GNAS (GNAS Complex Locus), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Aldosterone synthesis and secretion. The drugs Prednisone and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and brain, and related phenotypes are endocrine/exocrine gland and growth/size/body region

MedlinePlus : 42 Your pituitary gland is a pea-sized gland at the base of your brain. The pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body. Pituitary tumors are common, but often they don't cause health problems. Most people with pituitary tumors never even know they have them. The most common type of pituitary tumor produces hormones and disrupts the balance of hormones in your body. This can cause endocrine diseases such as Cushing's syndrome and hyperthyroidism. Symptoms of pituitary tumors include Headaches Vision problems Nausea and vomiting Problems caused by the production of too many hormones Pituitary tumors are usually curable. Treatment is often surgery to remove the tumor. Other options include medicines, radiation therapy, and chemotherapy.

Related Diseases for Pituitary Tumors

Diseases related to Pituitary Tumors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 450)
# Related Disease Score Top Affiliating Genes
1 prolactin producing pituitary tumor 33.8 PRL POMC
2 tsh producing pituitary tumor 33.3 SSTR5 SST PRL GH1
3 galactorrhea 32.7 PRL IGF1
4 gigantism 32.1 PRL GH1 AIP
5 familial isolated pituitary adenoma 31.6 MEN1 CNC2 AIP
6 empty sella syndrome 31.5 PROP1 PRL POMC IGF1 GH1
7 pituitary adenoma 1, multiple types 31.3 SST PRL MEN1 IGF1 GH1 AIP
8 primary pigmented nodular adrenocortical disease 30.5 POMC MEN1 GNAS CNC2
9 acth-secreting pituitary adenoma 30.5 SSTR5 SST PRL POMC MEN1 AIP
10 diabetes insipidus 30.4 PRL POMC GH1
11 non-functioning pituitary adenoma 30.4 SST GH1
12 amenorrhea 30.4 PRL POMC IGF1
13 insulin-like growth factor i 30.2 PRL IGF1 GH1
14 precocious puberty 30.2 GNAS GH1
15 pituitary apoplexy 30.2 SST PRL POMC MEN1 IGF1 GH1
16 chromophobe adenoma 30.0 PRL POMC GH1
17 goiter 30.0 SST PRL IGF1 GNAS
18 lymphocytic hypophysitis 30.0 POMC GH1
19 hormone producing pituitary cancer 29.9 SSTR5 SST PRL POMC MEN1 IGF1
20 chiasmal syndrome 29.9 SST POMC
21 cranial nerve palsy 29.9 PRL POMC
22 hypopituitarism 29.8 PROP1 PRL POMC IGF1 GH1
23 craniopharyngioma 29.8 PTTG1 PROP1 PRL IGF1 GH1
24 dowling-degos disease 1 29.8 POMC GNAS
25 pituitary stalk interruption syndrome 29.7 PRL GH1
26 small cell cancer of the lung 29.7 SST RB1 POMC
27 gangliocytoma 29.7 PRL POMC
28 acth-dependent cushing syndrome 29.6 PRL POMC
29 hyperprolactinemia 29.6 SST PRL POMC IGF1 GNAS GH1
30 ectopic cushing syndrome 29.6 SST POMC
31 abducens nerve disease 29.5 PRL POMC
32 insulinoma 29.5 SSTR5 SST MEN1
33 adenohypophysitis 29.5 PRL POMC GH1
34 acanthosis nigricans 29.5 PRL IGF1 GH1
35 pituitary hormone deficiency, combined, 2 29.4 PROP1 PRL POMC IGF1 GH1
36 neuroendocrine tumor 29.4 SST POMC MEN1
37 hyperthyroidism 29.4 SST PRL POMC IGF1 GNAS GH1
38 thyroid gland medullary carcinoma 29.3 SSTR5 SST MEN1
39 nelson syndrome 29.3 SSTR5 SST PRL POMC
40 multiple endocrine neoplasia, type iv 29.3 MEN1 GNAS AIP
41 sexual disorder 29.2 PRL POMC IGF1
42 intracranial hypertension, idiopathic 29.2 POMC IGF1 GH1
43 ovarian disease 29.1 PRL POMC IGF1 GH1
44 mccune-albright syndrome 29.1 SST PRL MEN1 IGF1 GNAS GH1
45 primary hyperparathyroidism 29.0 PRL POMC MEN1 IGF1
46 hypoglycemia 29.0 SST PRL POMC IGF1 GH1
47 hypothyroidism, congenital, nongoitrous, 4 29.0 PROP1 PRL POMC GH1
48 hypothyroidism 28.9 SST PROP1 PRL POMC IGF1 GNAS
49 pheochromocytoma 28.7 SST PRL POMC MEN1 IGF1
50 glucose intolerance 28.7 POMC IGF1 GH1

Graphical network of the top 20 diseases related to Pituitary Tumors:



Diseases related to Pituitary Tumors

Symptoms & Phenotypes for Pituitary Tumors

MGI Mouse Phenotypes related to Pituitary Tumors:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.07 AIP GNAS IGF1 MEN1 POMC PRL
2 growth/size/body region MP:0005378 10.02 AIP GNAS IGF1 MEN1 POMC PROP1
3 homeostasis/metabolism MP:0005376 10 AIP GNAS IGF1 MEN1 POMC PRL
4 liver/biliary system MP:0005370 9.63 AIP GNAS MEN1 POMC PRL RB1
5 neoplasm MP:0002006 9.5 AIP GNAS IGF1 MEN1 POMC PRL
6 nervous system MP:0003631 9.28 GNAS IGF1 MEN1 POMC PRL PROP1

Drugs & Therapeutics for Pituitary Tumors

Drugs for Pituitary Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Acetaminophen Approved Phase 4 103-90-2 1983
3
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
4
Ibuprofen Approved Phase 4 15687-27-1 3672
5
Morphine Approved, Investigational Phase 4 57-27-2 5288826
6
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
7
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
8
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
9
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
10
leucovorin Approved Phase 4 58-05-9 6006 143
11
Cefazolin Approved Phase 4 25953-19-9 656510 33255
12
Cefdinir Approved Phase 4 91832-40-5 6915944
13
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
14
Sulfamethoxazole Approved Phase 4 723-46-6 5329
15
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
16
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
17
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
18
Cabergoline Approved Phase 4 81409-90-7 54746
19
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
20
lanreotide Approved Phase 4 108736-35-2
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
22 Analgesics Phase 4
23 Analgesics, Non-Narcotic Phase 4
24 Narcotics Phase 4
25 Analgesics, Opioid Phase 4
26 Cyclooxygenase Inhibitors Phase 4
27 Anti-Inflammatory Agents, Non-Steroidal Phase 4
28 Antirheumatic Agents Phase 4
29 Insulin, Globin Zinc Phase 4
30 insulin Phase 4
31 Anti-Bacterial Agents Phase 4
32 Antibiotics, Antitubercular Phase 4
33 Cardiotonic Agents Phase 4
34 Sympathomimetics Phase 4
35 Protective Agents Phase 4
36 Vitamin B Complex Phase 4
37 Folate Phase 4
38 Vitamin B9 Phase 4
39 Cytochrome P-450 Enzyme Inhibitors Phase 4
40 Anti-Infective Agents Phase 4
41 cefuroxime axetil Phase 4
42 Folic Acid Antagonists Phase 4
43 Cephalosporins Phase 4
44 Clindamycin phosphate Phase 4
45 Antiprotozoal Agents Phase 4
46 Clindamycin palmitate Phase 4
47 Antiparasitic Agents Phase 4
48 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
49 Antimalarials Phase 4
50 Neurotransmitter Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 145)
# Name Status NCT ID Phase Drugs
1 Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach Unknown status NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
2 Effect of Dexmedetomidine as Anesthetic Coadjuvant on Plasmatic Cortisol Response in Transsphenoidal Surgery for Pituitary Tumors Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
3 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
4 Metabolic, Cardiovascular and Body Composition Effects of Sandostatin LAR® Therapy of Acromegaly, Effect of Reduction of Serum Insulin-like Growth Factor 1 (IGF-1) Levels Into a New Normative Range Unknown status NCT01424241 Phase 4 Sandostatin LAR
5 Randomized, Double-Blind, Placebo-Controlled Trial Comparing Opioid-Sparing and Opioid-Containing Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
6 The Effects of Weekly Administration of 40 mg Pegvisomant or Placebo on Quality of Life and Insulin Sensitivity in Acromegalic Patients With Normal IGF-I Concentrations During Long-Term Treatment With Long-Acting Somatostatin Analogs Completed NCT00642720 Phase 4 Pegvisomant
7 Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study Completed NCT01371643 Phase 4 Octreotide LAR
8 Beneficial Effect of Dose Escalation of Octreotide-LAR as First-Line Therapy in Patients With Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
9 PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials Recruiting NCT04107480 Phase 4 Dopamine Agonists
10 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
11 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
12 A Pilot Study of Pre- and Post-operative Somatuline Depot Therapy in Acromegalic Patients Treated by Endonasal Endoscopic Surgery: Impact on Early Remission Rates and Perioperative Morbidity Terminated NCT01861717 Phase 4 lanreotide
13 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
14 Dopamine Agonist Cabergoline in Residual Clinically Nonfunctioning Pituitary Adenoma After Transphenoidal Surgery: A Single Center, Open Label and Randomized Clinical Trial Completed NCT03271918 Phase 3 Cabergoline
15 Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
16 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape). Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
17 A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3 Pasireotide;octreotide LAR 30mg;lanreotide ATG 120mg
18 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
19 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial Recruiting NCT02288962 Phase 3 cabergoline
20 An Open-Label Phase 3 Study of the Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess Recruiting NCT03882034 Phase 3 Pegvisomant
21 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma From an Endocrinological Point of View (MERGE Study): a Randomized, Phase 3 Trial Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
22 Radiotherapy Plus Concomitant Temozolomide for Refractory Pituitary Adenomas,A Randomized,Double-blind, Placebo-controlled Phase II Trial Not yet recruiting NCT04244708 Phase 2, Phase 3 Radiotherapy plus temozolomide
23 An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
24 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
25 A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Completed NCT01689727 Phase 2 Technetium Tc 99m EC20
26 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed NCT00939523 Phase 2 Lapatinib
27 An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma Completed NCT01283542 Phase 2 Pasireotide LAR
28 Study of Thyrotropin Releasing Hormone in Patients With Thyroid or Pituitary Abnormalities Completed NCT00054756 Phase 2 TRH (Thyrotropin Releasing Hormone)
29 Sandostatin LAR vs. Surgery in Acromegalics With Macroadenoma Completed NCT00001860 Phase 2 Sandostatin LAR Depot versus transsphenoidal surgery
30 A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease Completed NCT01915303 Phase 2 Pasireotide with or without cabergoline
31 Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Aggressive Pituitary Tumors Recruiting NCT04042753 Phase 2 Ipilimumab;Nivolumab;Nivolumab
32 The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease Recruiting NCT04339751 Phase 2 Vorinostat
33 Pilot Study of Pasireotide LAR Treatment of Silent Corticotrophin Pituitary Tumors and Effects on Plasma Levels of POMC Active, not recruiting NCT02749227 Phase 2 Pasireotide LAR
34 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability Active, not recruiting NCT03038308 Phase 1, Phase 2 Ropinirole
35 Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas Active, not recruiting NCT03930771 Phase 2 Capecitabine;Temozolomide
36 An Open-Label Randomized Controlled Trial (RCT) of 6 Weeks of Human Growth Hormone (HGH) Prior to Ovulation Induction for In Vitro Fertilization (IVF) Enrolling by invitation NCT02179255 Phase 1, Phase 2 Human Growth Hormone;Follicle Stimulating Hormone
37 A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas Not yet recruiting NCT04335357 Phase 2 TBR-760;Placebo
38 Rosiglitazone (Peroxisome Proliferating Activating Receptor-gamma {PPAR-y} Ligand) Treatment of Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
39 An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease Terminated NCT00612066 Phase 2 rosiglitazone maleate
40 An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
41 Effect of Pasireotide LAR on Gonadotroph Adenomas: A Pilot Study Terminated NCT00929669 Phase 2 pasireotide LAR
42 A Phase II Study of Photodynamic Therapy (PDT) With Photofrin® (IND 104,613) For Recurrent High Grade Gliomas in Adults Terminated NCT01966809 Phase 2 Photofrin photodynamic therapy.
43 An Open Label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Temozolomide Treatment in Patients With Invasive Pituitary Tumors Withdrawn NCT00601289 Phase 2 temozolomide
44 Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma Withdrawn NCT01203618 Phase 2 Farletuzumab
45 Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Metastatic or Incurable Neuroendocrine Tumors Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
46 Detection of Functioning Pituitary Microadenoma With Inconclusive MRI Findings: PET/MRI Versus PET/CT Unknown status NCT03404414 Phase 1 18F-FDG
47 A Phase I, Open-Label, Maximum Tolerated Single-Cycle and Four-Cycle Dose-Finding Study to Evaluation the Safety and Tolerability of 90Y-SMT 487 Administered by Intravenous Infusion to Subjects With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00006368 Phase 1
48 Photodynamic Therapy (PDT) for Poor Prognosis Recurrent/Refractory Malignant Brain Tumors - A Phase I Study Completed NCT01682746 Phase 1 Photofrin (porfimer sodium) & photodynamic therapy.
49 Co-registered Fluorescence-Enhanced Resection of Brain Tumors Stage I: Correlation With MR and Biopsy Completed NCT00870779 Phase 1 5-aminolevulinic acid
50 A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas Completed NCT00020579 Phase 1 entinostat

Search NIH Clinical Center for Pituitary Tumors

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Octreotide
Octreotide Acetate

Genetic Tests for Pituitary Tumors

Anatomical Context for Pituitary Tumors

MalaCards organs/tissues related to Pituitary Tumors:

40
Pituitary, Thyroid, Brain, Testes, Breast, Hypothalamus, Bone

Publications for Pituitary Tumors

Articles related to Pituitary Tumors:

(show top 50) (show all 6658)
# Title Authors PMID Year
1
Effect of Stereotactic Radiosurgery on Residual or Relapsed Pituitary Adenoma: A Systematic Review and Meta-Analysis. 42 61
31899390 2020
2
Pituitary-Tumor Endocrinopathies. 61 42
32130815 2020
3
Imaging findings in hypophysitis: a review. 42
31863360 2020
4
A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. 61 54
20233783 2010
5
Pituitary tumor transforming gene binding factor: a new gene in breast cancer. 61 54
20406982 2010
6
Immunohistochemical expression of pituitary tumor transforming gene (PTTG) in pituitary adenomas: a correlative study of tumor subtypes. 54 61
20106827 2010
7
Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. 61 54
19890024 2010
8
The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. 54 61
20068168 2010
9
Effect of PTTG on endogenous gene expression in HEK 293 cells. 61 54
19958546 2009
10
E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. 54 61
19837943 2009
11
Acromegaly pathogenesis and treatment. 61 54
19884662 2009
12
Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. 54 61
19637311 2009
13
Somatostatin analog and pegvisomant combination therapy for acromegaly. 54 61
19763127 2009
14
Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis. 54 61
19549593 2009
15
Lanreotide promotes apoptosis and is not radioprotective in GH3 cells. 61 54
19528243 2009
16
Familial pituitary tumor syndromes. 54 61
19564887 2009
17
Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. 61 54
19687170 2009
18
Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. 54 61
19401364 2009
19
Fibroblast growth factor-2 autofeedback regulation in pituitary folliculostellate TtT/GF cells. 54 61
19359387 2009
20
Pituitary enlargement in patients with PROP1 gene inactivating mutation represents cystic hyperplasia of the intermediate pituitary lobe. Histopathology and over 10 years follow-up of two patients. 61 54
19774847 2009
21
Novel oncogenic actions of TRbeta mutants in tumorigenesis. 61 54
19391168 2009
22
Serum ghrelin levels in growth hormone-sufficient and growth hormone-deficient patients during growth hormone-releasing hormone plus arginine test. 61 54
19636202 2009
23
PTTG overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. 54 61
19351864 2009
24
Spindle cell oncocytoma of the adenohypophysis: report of a case with marked cellular atypia and recurrence despite adjuvant treatment. 61 54
19353839 2009
25
Intrapituitary expression and regulation of the gp130 cytokine interleukin-6 and its implication in pituitary physiology and pathophysiology. 54 61
19236332 2009
26
RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors. 54 61
19020999 2009
27
The relationship between prolactin (PRL), leptin, nitric oxide (NO), and cytokines in patients with hyperprolactinemia. 61 54
18752070 2009
28
Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. 61 54
18791324 2009
29
The effects of hyperprolactinemia on bone and fat. 54 61
18338266 2009
30
Improvement of congestive heart failure after octreotide and transsphenoidal surgery in a patient with acromegaly. 61 54
19420816 2009
31
Activin, TGF-beta and menin in pituitary tumorigenesis. 54 61
20175454 2009
32
The molecular biology of pituitary tumors: a personal perspective. 61 54
19058014 2009
33
Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. 54 61
19318729 2009
34
Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas. 61 54
19188737 2009
35
Aryl hydrocarbon receptor-interacting protein and pituitary adenomas: a population-based study on subjects exposed to dioxin after the Seveso, Italy, accident. 54 61
18787049 2008
36
Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. 61 54
18708436 2008
37
Non-functioning pituitary adenomas infrequently harbor G-protein gene mutations. 61 54
19169048 2008
38
p21(Cip1) restrains pituitary tumor growth. 61 54
18981426 2008
39
Interferon-gamma inhibits cellular proliferation and ACTH production in corticotroph tumor cells through a novel janus kinases-signal transducer and activator of transcription 1/nuclear factor-kappa B inhibitory signaling pathway. 61 54
18715881 2008
40
Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. 54 61
18653781 2008
41
Hypophysectomy for prostate cancer: a revival of old knowledge? 54 61
18826367 2008
42
Metabolic implications of growth hormone therapy. 54 61
19020393 2008
43
Increased incidence of autoimmune thyroiditis in patients with antipsychotic-induced hyperprolactinemia. 54 61
18539008 2008
44
Estrogen receptors in human pituitary tumors. 61 54
18398784 2008
45
Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant. 54 61
18492755 2008
46
Effect of hyperprolactinemia during development in children and adolescents. 61 54
18816151 2008
47
In vitro testing of new somatostatin analogs on pituitary tumor cells. 61 54
18243520 2008
48
Levonorgestrel antagonism on estrogen-induced pituitary tumors is mediated by progesterone receptors. 61 54
18548383 2008
49
Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. 54 61
18230656 2008
50
Management of acromegaly: is there a role for primary medical therapy? 61 54
18163213 2008

Variations for Pituitary Tumors

Expression for Pituitary Tumors

Search GEO for disease gene expression data for Pituitary Tumors.

Pathways for Pituitary Tumors

GO Terms for Pituitary Tumors

Cellular components related to Pituitary Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome lumen GO:0031904 8.62 PRL GH1

Biological processes related to Pituitary Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.62 SSTR5 SST RB1 MEN1
2 regulation of multicellular organism growth GO:0040014 9.4 PRL IGF1
3 tissue homeostasis GO:0001894 9.37 RB1 GNAS
4 myoblast differentiation GO:0045445 9.26 RB1 IGF1
5 positive regulation of transcription regulatory region DNA binding GO:2000679 9.16 RB1 IGF1
6 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 8.96 PRL GH1
7 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 8.62 IGF1 GH1

Molecular functions related to Pituitary Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor receptor binding GO:0005159 9.16 IGF1 GNAS
2 hormone activity GO:0005179 9.02 SST PRL POMC IGF1 GH1
3 prolactin receptor binding GO:0005148 8.96 PRL GH1

Sources for Pituitary Tumors

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....